A Phase 1, Open Label, Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Pimavanserin in Adolescents with Psychiatric Disorders
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Pimavanserin (Primary)
- Indications Psychiatric disorders
- Focus Pharmacokinetics
- Sponsors Acadia Pharmaceuticals
- 01 Nov 2019 Status changed from recruiting to completed.
- 19 Jun 2019 Status has been changed to recruiting.
- 21 Nov 2018 New trial record